Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Curr Opin Pulm Med. 2020 Jul;26(4):346-358. doi: 10.1097/MCP.0000000000000686.
The essential role of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in lung cancer diagnosis and staging is now well established. With a growing body of evidence seen over the last decade, the objective of this article was to review the newest findings, provide evidence-based guidance to clinicians and identify areas for future research related to EBUS-TBNA and staging in lung cancer.
Recent literature regarding EBUS-TBNA for lung cancer staging was reviewed, with a focus on evidence published subsequent to the 2016 guideline on technical aspects of EBUS-TBNA by the American College of Chest Physicians (ACCP). New findings were reported for the following: role of rapid on-site cytological evaluation (ROSE), needle size, lymph node ultrasound characteristics, molecular testing, as well as practice patterns and gaps in quality of care.
Significant advances in EBUS-TBNA have been realized since the publication of the 2016 ACCP guideline. Future areas of investigation have been identified and will require collaboration between centers of expertise. Additional work will be required to translate these technological advances into improved value-based care in the lung cancer population.
支气管内超声引导经支气管针吸活检术（EBUS-TBNA）在肺癌诊断和分期中的重要作用已得到充分证实。在过去十年中，越来越多的证据表明，本文的目的是回顾最新发现，为临床医生提供循证指导，并确定与 EBUS-TBNA 及肺癌分期相关的未来研究领域。
本文对肺癌分期的 EBUS-TBNA 相关文献进行了综述，重点关注美国胸科医师学会（ACCP） 2016 年发布的 EBUS-TBNA 技术方面指南之后发表的新证据。以下方面有新的发现：快速现场细胞学评估（ROSE）的作用、针的大小、淋巴结超声特征、分子检测以及实践模式和护理质量差距。
自 2016 年 ACCP 指南发布以来，EBUS-TBNA 取得了重大进展。已经确定了未来的研究领域，需要专家中心之间的合作。需要进一步的工作将这些技术进步转化为肺癌患者基于价值的更好的医疗服务。
